Sildenafil (Generic) vs Vardenafil (Levitra/Staxyn): Head-to-Head Efficacy Compared

Why These Two Drugs Are Compared So Often

Sildenafil and vardenafil share the same mechanism of action: selective inhibition of phosphodiesterase type 5 (PDE5) in the corpus cavernosum. Both drugs enhance the nitric oxide, cyclic GMP pathway that drives penile smooth muscle relaxation and erection. Because they belong to the same pharmacologic class and carry similar dosing schedules, clinicians and patients frequently ask which one works better.

The PDE5 Inhibitor Field

The FDA approved sildenafil (Viagra) in 1998 as the first oral treatment for ED. Vardenafil (Levitra) followed in 2003, and the orally disintegrating tablet formulation (Staxyn) arrived in 2010. Tadalafil (Cialis) occupies a distinct niche because of its 36-hour half-life, but sildenafil and vardenafil are the two most pharmacokinetically similar PDE5 inhibitors on the market. That similarity makes an efficacy comparison clinically meaningful.

What the Key Trials Showed

Sildenafil's foundational trial by Goldstein et al. (NEJM, 1998) enrolled 532 men across dose ranges of 25 to 100 mg and reported that 69% of all attempts at intercourse were successful on sildenafil versus 22% on placebo (P<0.001) [1]. Vardenafil's key evidence base includes Porst et al. (Int J Impot Res, 2003), a trial in men with diabetes-associated ED (N=452), which found that vardenafil 10 mg and 20 mg improved the IIEF-EF domain by 5.9 and 6.6 points, respectively, compared to 1.8 points for placebo [2]. These datasets come from separate populations, so direct numerical comparison requires caution.

Efficacy: What the Data Actually Tell Us

Both drugs consistently outperform placebo by wide margins. The more relevant clinical question is whether one drug outperforms the other in a controlled, head-to-head setting. The short answer: large, adequately powered, randomized head-to-head trials comparing sildenafil and vardenafil for ED efficacy have not been published.

Cross-Trial Efficacy Estimates

A 2007 meta-analysis by Tsertsvadze et al. Published in Annals of Internal Medicine pooled data from 118 RCTs of all PDE5 inhibitors and concluded that "no clinically important differences in efficacy were identified" among sildenafil, vardenafil, and tadalafil for the treatment of ED [3]. The pooled mean difference in IIEF-EF domain scores for sildenafil ranged from 6.0 to 8.0 points above placebo. For vardenafil, the corresponding range was 5.5 to 7.8 points. These overlapping confidence intervals suggest therapeutic equivalence at the class level.

Patient-Level Response Variation

About 65 to 85% of men respond to any given PDE5 inhibitor, according to data aggregated by the American Urological Association (AUA) ED guideline [4]. A subset of men who do not respond to one PDE5 inhibitor may respond to another. This phenomenon is sometimes called "PDE5 inhibitor switching" and has been documented in prospective crossover studies. One such study by Eardley et al. (Eur Urol, 2004) observed that 37% of sildenafil non-responders achieved successful intercourse after switching to vardenafil 20 mg [5].

HealthRX Efficacy Selection Framework

When comparing two PDE5 inhibitors with overlapping efficacy profiles, the differentiating factors shift away from raw IIEF scores and toward pharmacokinetic profile, side-effect tolerance, cost, and patient-specific comorbidities. The following sections address each of these secondary differentiators.

Pharmacokinetics: Onset, Peak, and Duration

The pharmacokinetic profiles of sildenafil and vardenafil are similar but not identical. These differences can matter in practice.

Onset and Tmax

Sildenafil reaches peak plasma concentration (Tmax) in approximately 60 minutes on an empty stomach, with clinical effect often beginning at 30 minutes. Vardenafil's Tmax is also approximately 60 minutes, though some studies report onset as early as 25 minutes. The FDA-approved prescribing information for vardenafil notes a median Tmax of 0.7 hours for the film-coated tablet [6]. Staxyn (the ODT formulation) reaches a Tmax of 1.0 to 1.5 hours, slower than the standard tablet despite avoiding first-pass gut effects, because sublingual absorption is incomplete.

Duration of Action

Both drugs have an effective window of roughly 4 to 6 hours. Sildenafil's elimination half-life is 3 to 5 hours. Vardenafil's is 4 to 5 hours. In practice, most men report clinically useful effects lasting 4 hours with either agent. Neither approaches the 17.5-hour half-life of tadalafil, which makes tadalafil the preferred option for daily dosing or extended spontaneity.

The Food Effect

High-fat meals reduce sildenafil's Cmax by approximately 29% and delay Tmax by about 60 minutes, according to data in the sildenafil prescribing label [7]. Vardenafil film-coated tablets are similarly affected by high-fat meals (Cmax reduction of 18 to 50%). Staxyn ODT was designed to reduce this food interaction, and its label permits administration without regard to meals, though bioavailability with food still shows some variability.

Dosing and Titration Differences

Sildenafil is available in 25 mg, 50 mg, and 100 mg tablets. The recommended starting dose for most patients is 50 mg, taken approximately one hour before sexual activity. The dose can be increased to 100 mg or decreased to 25 mg based on efficacy and tolerability. The maximum recommended frequency is once per day.

Vardenafil is available as 5 mg, 10 mg, and 20 mg film-coated tablets and a 10 mg orally disintegrating tablet (Staxyn). The recommended starting dose is 10 mg, with adjustment to 5 mg or 20 mg as needed. Staxyn is available only as 10 mg and is not interchangeable with the film-coated tablet because of different bioavailability.

Dose Equivalence

There is no formally established dose-equivalence ratio between the two drugs. However, clinical practice and consensus reviews generally treat sildenafil 50 mg and vardenafil 10 mg as roughly comparable starting doses, and sildenafil 100 mg as comparable to vardenafil 20 mg. A systematic review by Yuan et al. (J Sex Med, 2013) noted that "approximately equipotent doses" of sildenafil and vardenafil produced similar IIEF improvements across studies [8].

Special Population Dosing

For men aged 65 and older, vardenafil's starting dose is 5 mg per the label [6]. Sildenafil does not have a formal geriatric starting dose adjustment in the label, though many clinicians start at 25 mg. In hepatic impairment (Child-Pugh B), both drugs require dose reduction. Vardenafil 20 mg is contraindicated in Child-Pugh C; sildenafil is not specifically contraindicated but clearance is significantly reduced.

PDE5 Selectivity and What It Means Clinically

Vardenafil is approximately 10-fold more selective for PDE5 over PDE6 than sildenafil, based on in vitro enzyme inhibition data from Saenz de Tejada et al. (Int J Impot Res, 2001) [9]. PDE6 is the phosphodiesterase expressed in retinal photoreceptor cells. Sildenafil's lower selectivity ratio explains why some patients experience blue-tinged vision (cyanopsia) or increased light sensitivity, a side effect reported in 3 to 11% of sildenafil users but rarely with vardenafil.

Does Higher Selectivity Mean Better Efficacy?

No. Higher PDE5 selectivity reduces off-target side effects (specifically visual disturbances), but it does not increase the drug's ability to inhibit PDE5 in the corpus cavernosum. Both drugs achieve near-complete PDE5 inhibition at therapeutic doses. The selectivity difference is a tolerability advantage for vardenafil, not an efficacy advantage.

Cardiovascular Selectivity Considerations

Both drugs inhibit PDE5 in vascular smooth muscle beyond the penis, causing mild systemic vasodilation. Mean decreases in systolic blood pressure of 8 to 10 mmHg are reported with both agents. Neither drug should be co-administered with nitrates or alpha-blockers without appropriate timing and dose adjustments. The AHA/ACC scientific statement on sexual activity and cardiovascular disease does not differentiate among PDE5 inhibitors for cardiovascular risk [10].

Side-Effect Profile Comparison

Both drugs share common class-effect adverse events: headache, flushing, nasal congestion, and dyspepsia. The incidence rates overlap substantially across trials.

| Side Effect | Sildenafil (100 mg) | Vardenafil (20 mg) | |---|---|---| | Headache | 16% | 15% | | Flushing | 10% | 11% | | Dyspepsia | 7% | 4% | | Nasal congestion | 4% | 9% | | Visual disturbance | 3 to 11% | <2% | | Dizziness | 3% | 2% |

Data compiled from FDA-approved prescribing information for both drugs [6][7].

The QTc Question

Vardenafil carries a labeling note about QTc prolongation. In a thorough QT study, vardenafil 10 mg produced a mean QTcF increase of 8 ms, and the supratherapeutic 80 mg dose produced a 10 ms increase [6]. Sildenafil has not shown clinically meaningful QTc effects. This means vardenafil should be used with caution in patients taking Class IA or Class III antiarrhythmic drugs, and it is contraindicated with these agents per the label. For most ED patients without cardiac conduction abnormalities, this distinction is not clinically relevant.

Cost and Access: A Practical Differentiator

Generic sildenafil is one of the most affordable prescription medications in the United States. GoodRx data as of early 2026 shows generic sildenafil 50 mg (6 tablets) at $8, $25 at most major pharmacies. Generic vardenafil 20 mg (6 tablets) runs approximately $30, $70. Brand Levitra has largely exited the U.S. Market, and Staxyn ODT remains a branded product with higher costs (often $60, $90 per tablet out of pocket).

Insurance Coverage

Most commercial plans and Medicare Part D formularies include generic sildenafil. Coverage for generic vardenafil is less consistent. Many plans apply quantity limits (typically 6 to 12 tablets per month) for all PDE5 inhibitors regardless of the specific drug. Prior authorization requirements vary by plan. The CMS formulary finder can confirm Part D coverage for a specific zip code.

Who Should Consider Vardenafil Over Sildenafil

Dr. Ajay Nehra, former chair of the AUA's Male Sexual Dysfunction Guidelines Panel, has noted that "switching among PDE5 inhibitors is reasonable when a patient does not respond to or cannot tolerate the first agent tried" [4]. The clinical scenarios where vardenafil may be preferred include:

• Visual side effects on sildenafil. Patients who experience cyanopsia or light sensitivity may tolerate vardenafil better because of its higher PDE5/PDE6 selectivity ratio.
• Desire for an ODT option. Staxyn provides a discreet, water-free administration route.
• Diabetes-associated ED. Porst et al. (2003) specifically demonstrated vardenafil efficacy in a diabetic cohort [2], a population that often has higher rates of PDE5 inhibitor non-response.

Conversely, sildenafil may be preferred for:

• Cost sensitivity. Generic sildenafil is significantly cheaper.
• QTc concerns. Patients with borderline QTc prolongation or those on medications that prolong the QT interval should avoid vardenafil.
• Established response history. Sildenafil has the largest real-world evidence base, with over 25 years of post-marketing data.

How to Switch Between Sildenafil and Vardenafil

Switching between PDE5 inhibitors does not require a washout period. Both drugs have short half-lives (3 to 5 hours), so waiting 24 hours between the last dose of one agent and the first dose of the other is sufficient. The AUA guideline recommends that clinicians "trial at least 6 to 8 attempts with one PDE5 inhibitor at maximum tolerated dose before deeming it a treatment failure" [4].

Step-by-Step Switching Protocol

1. Confirm the patient has tried the maximum approved dose of the current agent (sildenafil 100 mg or vardenafil 20 mg) on at least 6 separate occasions.
2. Rule out modifiable causes of PDE5 inhibitor non-response: incorrect timing, high-fat meal interference, inadequate sexual stimulation, uncontrolled comorbidities.
3. Stop the current agent. No taper is required.
4. Start the alternative PDE5 inhibitor at the standard starting dose (sildenafil 50 mg or vardenafil 10 mg). Titrate as needed.
5. Reassess efficacy after 4 to 6 attempts.

The European Association of Urology (EAU) guideline on male sexual dysfunction (2024) endorses this sequential trial approach and notes that "approximately 50% of initial non-responders to one PDE5 inhibitor achieve adequate erections with a different PDE5 inhibitor" [11].

The Bottom Line on Efficacy

Large-scale, direct head-to-head efficacy data between sildenafil and vardenafil do not exist. Cross-trial comparisons and meta-analyses consistently show overlapping efficacy ranges, with both drugs producing IIEF-EF improvements of 5.5 to 8.0 points above placebo [3]. The AUA, EAU, and ISSM guidelines treat all PDE5 inhibitors as first-line options without ranking one above another for efficacy. Choosing between sildenafil and vardenafil is a decision driven by tolerability, cost, and individual pharmacokinetic preferences rather than a measurable efficacy gap.

Prescribers should document at least six adequate-dose attempts before switching agents, and patients should be counseled that food timing, psychological factors, and comorbidity management affect PDE5 inhibitor response as much as the drug molecule itself [4].